Nick combines years of life sciences strategy and policy consulting experience with a heartfelt commitment to connecting the right patients to the life-saving therapies they need. He is skilled at helping manufacturers navigate complex global access and reimbursement landscapes and optimize their strategies to communicate the value of their innovation to patients, providers, and payers. Nick has advised clients on brand, commercial, pricing, and market access strategies for primary and specialty care products, ranging from small molecules, to biologics, to cell and gene therapies.
Prior to joining Blue Fin Group, Nick managed global commercial strategy engagements with biopharmaceutical and biotech clients at IQVIA and Boston Healthcare Associates. He also advised manufacturers on complex pricing and reimbursement policy issues at the Pharmaceutical Research and Manufacturers of America (PhRMA).